Correction to: Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center

被引：0
|
作者：
Yosuke Kano
Manabu Ohashi
Naoki Hiki
Daisuke Takahari
Keisho Chin
Kensei Yamaguchi
Yasuo Tsuda
Yoshiaki Shoji
Itaru Yasufuku
Kojiro Eto
Satoshi Ida
Koshi Kumagai
Souya Nunobe
Takeshi Sano
机构：
[1] Japanese Foundation for Cancer Research,Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital
[2] Japanese Foundation for Cancer Research,Department of Gastroenterological Medicine, Gastroenterological Center, Cancer Institute Hospital
来源：
Gastric Cancer | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the original publication of this article, the 5-year OS rates of the S-1 group in the ACTS-GC according to TNM-6 were described incorrectly in Table 4. The revised Table 4 is given in this correction.
引用
收藏
页码：1072 / 1072
相关论文
共 50 条
  • [31] A phase III trial to confirm the superiority of S-1 adjuvant chemotherapy for vulnerable elderly patients with pathological stage II/III gastric cancer after curative resection: JCOG1507 (BIRDIE).
    Yamaguchi, Kazuya
    Yoshida, Kazuhiro
    Mizusawa, Junki
    Mizutani, Tomonori
    Ito, Seiji
    Nishida, Yasunori
    Yabusaki, Hiroshi
    Sano, Takeshi
    Sasako, Mitsuru
    Katayama, Hiroshi
    Fukuda, Haruhiko
    Boku, Narikazu
    Yoshikawa, Takaki
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)
    Fujitani, Kazumasa
    Tamura, Shigeyuki
    Kimura, Yutaka
    Matsuyama, Jin
    Imamura, Hiroshi
    Yamamoto, Kazuyoshi
    Fujita, Junya
    Iijima, Shohei
    Ueda, Shugo
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Satoh, Taroh
    GASTRIC CANCER, 2020, 23 (03) : 520 - 530
  • [33] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)
    Ryohei, Kawabata
    Kazumasa, Fujitani
    Shigeyuki, Tamura
    Yutaka, Kimura
    Hiroshi, Imamura
    Junya, Fujita
    Jin, Matsuyama
    Shohei, Iijima
    Shugo, Ueda
    Yukinori, Kurokawa
    Daisuke, Sakai
    Toshio, Shimokawa
    Toshimasa, Tsujinaka
    Hiroshi, Furukawa
    Taroh, Satoh
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002)
    Kazumasa Fujitani
    Shigeyuki Tamura
    Yutaka Kimura
    Jin Matsuyama
    Hiroshi Imamura
    Kazuyoshi Yamamoto
    Junya Fujita
    Shohei Iijima
    Shugo Ueda
    Yukinori Kurokawa
    Toshio Shimokawa
    Taroh Satoh
    Gastric Cancer, 2020, 23 : 520 - 530
  • [35] Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment
    Kadowaki, Shigenori
    Komori, Azusa
    Narita, Yukiya
    Nitta, Sohei
    Yamaguchi, Kazuhisa
    Kondo, Chihiro
    Taniguchi, Hiroya
    Takahari, Daisuke
    Ura, Takashi
    Ando, Masashi
    Muro, Kei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 656 - 661
  • [36] Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment
    Shigenori Kadowaki
    Azusa Komori
    Yukiya Narita
    Sohei Nitta
    Kazuhisa Yamaguchi
    Chihiro Kondo
    Hiroya Taniguchi
    Daisuke Takahari
    Takashi Ura
    Masashi Ando
    Kei Muro
    International Journal of Clinical Oncology, 2014, 19 : 656 - 661
  • [37] Three-year outcomes of two phase II studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin in patients with stage III gastric cancer after D2 gastrectomy
    Nakamura, Yoshiaki
    Yamanaka, Takeharu
    Chin, Keisho
    Cho, Haruhiko
    Katai, Hitoshi
    Terashima, Masanori
    Ito, Seiji
    Hirao, Motohiro
    Yoshida, Kazuhiro
    Oki, Eiji
    Sasako, Mitsuru
    Emi, Yasunori
    Bando, Hideaki
    Kawashima, Yoshiyuki
    Fukunaga, Tetsu
    Gotoh, Masahiro
    Ishibashi, Takako
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
    Kimura, Yutaka
    Kawakami, Hisato
    Tamura, Shigeyuki
    Fujitani, Kazumasa
    Matsuyama, Jin
    Imamura, Hiroshi
    Iijima, Shohei
    Sakai, Daisuke
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    Satoh, Taroh
    GASTRIC CANCER, 2023, 26 (05) : 788 - 797
  • [39] Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
    Yutaka Kimura
    Hisato Kawakami
    Shigeyuki Tamura
    Kazumasa Fujitani
    Jin Matsuyama
    Hiroshi Imamura
    Shohei Iijima
    Daisuke Sakai
    Yukinori Kurokawa
    Toshio Shimokawa
    Toshimasa Tsujinaka
    Hiroshi Furukawa
    Taroh Satoh
    Gastric Cancer, 2023, 26 : 788 - 797
  • [40] Comparison of Long-Term Efficacy in S-1 and Capecitabine With Oxaliplatin as Adjuvant Chemotherapy for Patients With Gastric Cancer After Curative Surgery: A Retrospective, Single-Center Observational Study
    Oh, Sung E.
    An, Ji Y.
    Choi, Min-Gew
    Lee, Jun H.
    Sohn, Tae S.
    Bae, Jae M.
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
12345